Article

AMA to issue new code for conjunctivitis test

Rapid Pathogen Screening Inc. (RPS) has announced that the American Medical Association (AMA) will issue a new CPT code, 87809, for "Infectious agent antigen detection by immunoassay with direct optical observation; Adenovirus" to cover the company's proprietary test (Adeno Detector) effective Jan. 1.

Sarasota, FL-Rapid Pathogen Screening Inc. (RPS), a developer of point-of-care diagnostic devices for ocular diseases, has announced that the American Medical Association (AMA) will issue a new CPT code, 87809, for "Infectious agent antigen detection by immunoassay with direct optical observation; Adenovirus" to cover the company's proprietary test (Adeno Detector) effective Jan. 1.

The point-of-care test has been cleared by the FDA and waiver under the Clinical Laboratory Improvement Amendments of 1988. According to the company, it provides a definitive result in 10 minutes.

"The creation of a new CPT code reflects the value that the [test] provides to the patient, the clinician, and the health-care system at large," said Robert Sambursky, MD, chief medical officer, RPS. "With the CPT code, clinicians may use the [test] to diagnose and treat cases of acute conjunctivitis accurately. This not only will result in better patient care; it also will save millions in health-care dollars."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.